Onterris (NYSE:ONT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 17.5%

Onterris (NYSE:ONT) reported Q2 CY2026 revenue of $186.7 million, down 20.4% year on year, missing analysts’ estimates. The company’s full-year revenue guidance midpoint was $765 million, 10.9% below consensus. Non-GAAP EPS was $0.51, above estimates, and the stock fell 17.5% to $18.73 after results.

Original reporting
Published Aug 5, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Onterris (NYSE:ONT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 17.5% — source image
Decision brief

The 30-second read

$ONTBearishHigh
01

Why it matters

Q2 revenue fell 20.4% YoY to $186.7M and full-year revenue guidance of $765M midpoint came 10.9% below analysts, outweighing an adjusted EPS beat.

02

Market read

Traders are likely repricing Onterris’s revenue trajectory and guidance credibility after a revenue miss and below-consensus full-year revenue midpoint.

03

What to watch

The article notes non-GAAP profit strength and EPS inflection, but it does not quantify backlog, contract wins, or cash flow, which could explain the revenue decline.

Relevance 9/10Novelty 9/10Timing: post-results, same-day reaction after Q2 CY2026 results

Background

Onterris provides air quality monitoring, environmental laboratory testing, compliance, and environmental consulting services.

Company-level read

Ticker impact

$ONTBearishHigh confidence
Context

Onterris missed Q2 CY2026 revenue expectations and guided full-year revenue to $765M midpoint, 10.9% below analysts.

Expected impact

Bearish near-term bias; traders may fade rallies until guidance credibility improves.

Evidence & confidence

The article provides specific, time-sensitive datapoints: Q2 revenue down 20.4% YoY to $186.7M, full-year revenue guidance $765M midpoint (10.9% below estimates), and an immediate 17.5% post-results decline.

Market effects

Weak revenue guidance from an environmental services provider can pressure sentiment for similarly sized, margin-sensitive industrial services names.

No specific regional spillover is described beyond the single-name move.

No global macro or cross-border catalyst is cited.

Counterpoint

Adjusted EPS beat consensus ($0.51 vs estimates) and management guided EPS growth, suggesting the market may be over-penalizing revenue softness.

Key entities

  • Onterris

    Environmental services provider reporting Q2 CY2026 results and full-year revenue guidance.

  • Wall Street analysts

    Consensus estimates referenced for Q2 revenue and full-year revenue guidance comparisons.

Related articles

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock rallying today?

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.

$ONTHigh

Onterris, Inc. (ONT): Results of Operations and Financial Condition

Onterris, Inc. (ONT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Onterris Reports Second Quarter Results, Updates Full-Year 2026 Guidance, and Announces Board-led Strategic Review Process Updates Date and Time of Conference Call to Today, Wednesday, August 5, at 5:30 p.m. Eastern Time Second Quarter 2026 Highlights (comparisons to

$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.